ImmunityBio (IBRX) Other Accumulated Expenses (2014 - 2026)

ImmunityBio (IBRX) has reported Other Accumulated Expenses for 13 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 7.58% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 7.58% YoY), while the FY2025 annual figure was $3.1 million, up 192.67% from the prior year.
• Other Accumulated Expenses eased to $2.4 million in Q1 2026 per IBRX's latest filing, from $3.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.1 million in Q4 2025 and bottomed at $556000.0 in Q1 2024.
• Historically, Other Accumulated Expenses has averaged $1.6 million across 5 years, with a median of $1.5 million in 2022.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses plunged 65.82% — and 2025, when it surged 376.8%.
• ImmunityBio's Other Accumulated Expenses stood at $1.6 million in 2022, then tumbled by 56.02% to $716000.0 in 2023, then jumped by 46.65% to $1.0 million in 2024, then jumped by 192.67% to $3.1 million in 2025, then declined by 20.27% to $2.4 million in 2026.
• Business Quant data shows IBRX's Other Accumulated Expenses at $2.4 million in Q1 2026, $3.1 million in Q4 2025, and $2.1 million in Q3 2025.